포스터 다운로드_Biocytogen Pharmaceuticals (Beijing) Co., Ltd._Biocytogen, drug development, antibody discovery

top

Please input keywords

KR

사회적 책임

합작연구개발

Project Integrum

Antibody discovery platforms

Clinical pipeline

Preclinical pipeline

동물/세포 모델

Pharmacology service

유전자 편집

Stock Information

Financial Reports

Listing Documents

Announcements & Notices

Corporate Governance

Investor Calendar

자료 다운로드

포스터 다운로드

홍보센터

뉴스 및 각종 자료 열람

논문게재실적

자료 다운로드

포스터 다운로드

제품정보 다운로드

SITC 2023: *DM001, a Novel TROP2xEGFR Bispecific ADC, Demonstrates Potent Tumor Growth Inhibition in Preclinical Models and Favorable Safety Profile in Cynomolgus Monkey

SITC 2023: Preclinical Evaluation of Fully Human Bispecific Antibody-drug Candidates Targeting HER3 and the Juxtamembrane Region of MUC1

SITC 2023: *DM005, an EGFR х MET Bispecific Antibody-drug Conjugate With a Novel DNA Topoisomerase I Inhibitor Payload, Showed Robust Anti-tumor Activity in Preclinical Models

SITC 2023: BSA01, a Bispecific Antibody-drug Conjugate Targeting EGFR and Membrane-bound MUC1-C, Exhibits Anti-tumor Efficacy In Vivo Efficacy Against Triple-negative Breast Cancer Xenografts

SITC 2023: BCG022: A HER3×MET Bispecific Antibody-drug Conjugate (BsADC) Targeting Key Mechanisms of Bypass Resistance in Multiple Tumor Types

SITC 2023: A Novel Bispecific Antibody-drug Conjugate Targeting PTK7 and TROP2, BCG033, Demonstrates Preclinical Efficacy Against Triple-negative Breast Cancer Xenografts

SITC 2023: Identification of fully human TCR-mimic antibodies targeting the KRAS G12V/HLA complex generated in HLA-transgenic RenMab mice

SITC 2023: Preclinical Application of a Fully Human TCR-mimic Antibody Developed to Target NY-ESO-1/HLA-A02

SITC 2023: Fc-Competent Fully Human Anti-TIGIT Blocking Monoclonal Antibodies Demonstrated Potent Anti-Tumor Efficacy in Preclinical Models

1 2 3 4 5 … 9